Kiora Pharmaceuticals, Inc.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1 clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. Show More...

  • Website https://www.kiorapharma.com
  • Sector Healthcare
  • Industry Biotechnology
  • Last Quote 2.98 USD
  • Last Updated 30-05-2025
  • External Links Yahoo Finance Morningstar Ratios
  •   2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 2020-12 2021-12 TTM
    Earnings Per Share USD -469.29 -301.71 -138.0 -40.5 -22.65 -13.95 -4.57 -2.23 -1.77 -1.77 -1.77
    Dividends USD
    Payout Ratio % *
    Shares Mil 1.0 1.0 2.0 3.0 5.0 9.0 9.0
    Book Value Per Share * USD 17.0 4.81 0.59 3.8 1.28 1.07 1.37 0.73
    Free Cash Flow Per Share * USD -6.55 -14.33 -8.54 -5.51 -2.55 -1.89 -1.29
    Return on Assets % -257.57 -255.65 -169.06 -304.47 -138.72 -109.98 -75.64 -58.19 -64.04 -98.72 -98.72
    Financial Leverage (Average) 1.56 1.6 1.52 2.17 1.96 1.96
    Return on Equity % -463.53 -308.49 -91.23 -118.81 -202.11 -202.11
    Return on Invested Capital % -459.07 -310.05 -91.71 -112.72 -195.16 -195.16
    Interest Coverage -5.02 -2.51 -3.34
    Current Ratio 2.75 0.22 0.04 2.76 0.57 0.57 2.19 3.06 1.02 5.59 5.59
    Quick Ratio 2.69 0.21 0.04 2.73 0.5 0.53 2.08 2.67 0.72 5.21 5.21
    Debt/Equity 0.04 0.010 0.010